Galvani Bioelectronics

Galvani Bioelectronics
Subsidiary
Industry Bioelectronics
Founded November 2016[1]
Founders

[2][3]

Headquarters Stevenage[4], United Kingdom[1][2]
Key people
 Kristoffer Famm (President)[5]
Parent GlaxoSmithKline (55% equity interest)[2]
Website galvani.bio

Galvani Bioelectronics is a United Kingdom-based bioelectronics R&D company founded by Alphabet Inc. subsidiary Verily Life Sciences and British pharmaceutical company GlaxoSmithKline (GSK) in November 2016.[1][3] The partnership to form the company was announced on 1 August 2016.[2]

Verily has a 45% equity interest while GSK has a 55% equity interest, making GSK the effective owner. The initial agreed upon investment between the two companies is up to £540 million over a period of seven years. Additionally, both companies agreed to contribute their existing intellectual property rights.[2]

References

  1. 1 2 3 "Galvani Bioelectronics Website". Galvani Bioelectronics. Retrieved 24 December 2016.
  2. 1 2 3 4 5 "GSK and Verily to establish Galvani Bioelectronics – a new company dedicated to the development of bioelectronic medicines". GlaxoSmithKline. 1 August 2016. Retrieved 24 December 2016.
  3. 1 2 "Galvani Bioelectronics". Verily Life Sciences website. Retrieved 24 December 2016.
  4. ↑ Temperton, James (1 August 2016). "GSK and Google just created a £540m bioelectronic health firm". Wired (website). Retrieved 24 December 2016.
  5. ↑ "Kristoffer Famm Ph.D. - Galvani Bioelectronics". Galvani Bioelectronics. Retrieved 25 December 2016.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.